Risk of Alzheimer's disease–related medication prescriptions in patients with type 2 diabetes (with obesity) (comparison between matched semaglutide vs other anti–diabetes medications groups)

Size/Group	Exposure Group	Comparison Group	Exposure Group Cases (Overall Risk)	Comparison Group Cases(Overall Risk)		HR (95% CI)
9,533	Semaglutide	Insulin	54 (0.57%)	95 (1.00%)		0.51 (0.36–0.71)
9,530	Semaglutide	Metformin	53 (0.56%)	87 (0.91%)		0.58 (0.41–0.81)
8,224	Semaglutide	DPP–4i	47 (0.57%)	91 (1.11%)		0.47 (0.33–0.68)
7,649	Semaglutide	SGLT2i	43 (0.56%)	65 (0.85%)		0.61 (0.42–0.90)
8,867	Semaglutide	SU	51 (0.58%)	94 (1.06%)		0.50 (0.36–0.70)
4,256	Semaglutide	TZD	33 (0.78%)	61 (1.43%)		0.49 (0.32–0.74)
9,448	Semaglutide	Other GLP–1RAs	54 (0.57%)	82 (0.87%)		0.64 (0.45–0.90)

Hazard Ratio (HR)

0.10 0.20 0.40 0.70 2.0 3.00 5.00 8.00